and the rest, unfortunately. Marketing seems to be outweighing the standard 10% by double, from what I gather and bonus’s in co-hoots. Looking fwd to figures that add to shareholder value, not just partners, in near future. Willis on 17% I believe if they meet the ebitda 2million . Something. Please DYOR
Ann: FDA Framework and New Operation Fly Formula, page-14
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BUB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.010(8.33%) |
Mkt cap ! $116.1M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $669.0K | 5.144M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 522245 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 668951 | 13 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| BUB (ASX) Chart |